People with multiple sclerosis (MS) reported improvements in physical and mental quality of life along with reduced depression after one year of treatment with an ocrelizumab biosimilar, according to a small study conducted in Iran. The observational study followed 30 adults with MS who received Xacrel, an ocrelizumab biosimilar approved in Iran, and assessed patient-reported…

By: Dr. Eva Jackson Rethinking Goal Setting in Our Community For the past 15 years, members of my community have routinely organized vision board parties toward the end of the year or at the start of the new year, with … Continue reading → Source: blog.mymsaa.org

Older adults with multiple sclerosis (MS) show a higher prevalence and severity of cognitive impairment — particularly affecting information processing speed and memory — than younger patients, a new study reports. However, age was not directly associated with cognitive impairment, the results showed. Instead, greater disability emerged as the main predictor of such problems in…

Oligodendrocytes, the cells responsible for making myelin, are constantly being made throughout the brain and spinal cord, even when there’s no myelin damage, according to a new study by U.S. researchers. These findings challenge the long-held view that oligodendrocyte precursor cells mostly differentiate into oligodendrocytes at sites of damage to drive myelin repair. Instead, this…

A new year, a new malady Did you know that “raja” is a legitimate Scrabble word? I didn’t and I’m a pretty decent Scrabble player. In fact, my friend’s niece thinks I am a Scrabble queen because I taught her about adding an s, r or d to a word and making a new word…

About two years after my multiple sclerosis (MS) diagnosis, I began having hand-related symptoms that interfered with my daily life and caused significant stress. I’m a college student and remote employee, so I spend a lot of time typing, which is considered a fine motor skill because of the coordination and precision required. The symptoms I…

Tweet Natalizumab is a migration inhibitor that works because it blocks lymphocytes and monocytes from migrating into the CNS and other tissues. It has been given as an intravenous infusion and more recently, as the patent runs out, as an injection under the skin. These both used to be given in hospital, but the latter…

The post From our CEO appeared first on MS Australia. Source: www.msaustralia.org.au

The post Tolebrutinib outcomes not as hoped for progressive MS appeared first on MS Australia. Source: www.msaustralia.org.au